CPT 0327U: Vasistera™ cfDNA Noninvasive Prenatal Test

Headline: CPT code 0327U: Proprietary Natera Vasistera™ cfDNA Noninvasive Prenatal Test

Lead: CPT code 0327U designates Vasistera™, a proprietary noninvasive prenatal test (NIPT) from Natera, Inc., that evaluates cell–free DNA (cfDNA) in maternal plasma to estimate the likelihood of fetal aneuploidies such as trisomy 21, 13, and 18. As a PLA code, 0327U is uniquely tied to a single manufacturer's commercial assay and is used when that specific test is performed.

What this code represents and why it matters: PLA codes like CPT code 0327U signal the growing role of manufacturer-specific genomic assays in prenatal screening. These tests influence clinical workflows for early pregnancy screening, laboratory operations for centralized cfDNA analysis, and payer coverage decisions given their proprietary nature.

Key payers covered: Analysis includes major national payers: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Overview of reader takeaways: Readers will learn the clinical context of CPT code 0327U as a cfDNA-based NIPT, where the service is typically performed, and the implications of PLA designation for billing and payer policy. The publication provides benchmarks for usage and coverage trends, summarizes relevant payer approaches and policy updates, and explains operational considerations for laboratories and clinicians using proprietary NIPT platforms.

Scope: Content is national in scope and focuses on coding, clinical application, payer considerations, and operational context for CPT code 0327U.

Billing Code Overview

CPT code 0327U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the Vasistera™ noninvasive prenatal test from Natera, Inc. The assay uses cell–free DNA (cfDNA) from a maternal plasma specimen to analyze select fetal DNA sequences on an automated platform and applies an algorithm to calculate the likelihood of fetal aneuploidies, including trisomy 21 (Down syndrome), trisomy 13 (Edwards syndrome), and trisomy 18 (Patau syndrome).

Service Type: Noninvasive prenatal screening (NIPT) using maternal plasma cfDNA with algorithmic analysis

Typical Site of Service: Reference or specialty laboratory; specimen collection typically occurs in outpatient clinics or phlebotomy sites with testing performed in a centralized laboratory

Clinical Context

A pregnant patient in the first or early second trimester presents for prenatal screening and requests noninvasive prenatal testing (NIPT) for common fetal aneuploidies. The ordering clinician (obstetrician-gynecologist or maternal-fetal medicine specialist) documents gestational age, obstetric history, and indication such as advanced maternal age, positive maternal serum screen, abnormal ultrasound finding, or patient preference. A blood draw is performed in an ambulatory clinic or outpatient lab; a maternal plasma specimen is collected into appropriate cfDNA collection tubes, labeled, and shipped to the performing laboratory (Natera, Inc.). The laboratory performs the proprietary assay Vasistera™ using automated cfDNA extraction, targeted analysis of selected sequences, and an algorithm to calculate the likelihood of trisomy 21, trisomy 13, and trisomy 18. Results are reported to the ordering clinician with an interpretation indicating high‑ or low‑likelihood for each condition and recommended follow up options. Typical site of service is outpatient ambulatory care, obstetric clinic, or an independent clinical laboratory remote from the ordering site. Service type: Proprietary Laboratory Analyses (PLA) — high‑complexity molecular diagnostic test billed by the performing laboratory using code 0327U.

Coding Specifications

Modifier	Description	When to Use
`00`	Default/Not Applicable	Use when no other modifier applies; standard reporting for laboratory PLA service.

Taxonomy Code	Specialty	Notes
207V00000X	Obstetrics & Gynecology	Ordering clinicians for prenatal screening and NIPT.
207VT0006X	Maternal-Fetal Medicine	High‑risk pregnancy specialists who commonly order NIPT and manage abnormal results.
208D00000X	Clinical Laboratory	Performing laboratory directors and laboratory physicians overseeing cfDNA testing.
363A00000X	Clinical Genetics	Geneticists and genetic counselors who interpret results and counsel patients on implications.
367AG0400X	Molecular Pathology	Laboratory specialists responsible for high‑complexity molecular diagnostic assays and validation.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`Z36`	Encounter for antenatal screening of mother	Common primary code to indicate prenatal screening services such as NIPT are being performed.
`Z34.90`	Encounter for supervision of normal pregnancy, unspecified trimester, unspecified	Used when NIPT is performed during routine prenatal care in an otherwise uncomplicated pregnancy.
`O09.511`	Supervision of pregnancy with history of infertility, second trimester	NIPT may be used in pregnancies with assisted reproductive technologies or infertility history; trimester code selected per gestational age.
`O09.892`	Supervision of pregnancy with other poor reproductive or obstetric history, third trimester	Relevant when prior obstetric history raises concern for fetal aneuploidy risk and NIPT is considered.
`Z35.0`	Supervision of high‑risk pregnancy due to fetal problems	Used when ultrasound or other findings increase concern and advanced screening like NIPT is indicated.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`36415`	Collection of venous blood by venipuncture	Blood draw performed at the ordering site or lab to obtain the maternal plasma specimen for the NIPT assay.
`80061`	Lipid panel (cholesterol testing)	Example of routine prenatal laboratory panels often performed at the same visit; not specific to NIPT but commonly co‑ordered in prenatal care.
`81025`	Urine pregnancy test, qualitative	May be used earlier in prenatal workflow to confirm pregnancy prior to ordering NIPT; listed as commonly performed in prenatal clinics.
`76815`	Ultrasound, obstetrical; limited, first trimester (e.g., fetal heartbeat)	Ultrasound findings (dating or structural) commonly occur alongside NIPT decision-making and may inform indication for testing.
`99213`	Office or other outpatient visit for the evaluation and management of an established patient	Typical clinician visit where counseling, informed consent, and ordering of `0327U` occur.

OpenPayer

Summary & Overview